Studies reveal safe checkpoint inhibitors for cardiovascular toxicities
In the first scale investigation of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias that occur during the primary stage of treatment. The researchers used VigiBase, a global database of drug complications maintained by the World Health Organization, to track adverse cardiovascular reactions in the latest study. Apart from cardiovascular complications, checkpoint inhibitors may also stimulate reactions in the lungs, liver, and colon. With other complications, steroids are endorsed to relieve the resulting inflammation.